[go: up one dir, main page]

WO2009092810A3 - Composition pharmaceutique unique contenant des antibiotiques et des probiotiques - Google Patents

Composition pharmaceutique unique contenant des antibiotiques et des probiotiques Download PDF

Info

Publication number
WO2009092810A3
WO2009092810A3 PCT/EP2009/050803 EP2009050803W WO2009092810A3 WO 2009092810 A3 WO2009092810 A3 WO 2009092810A3 EP 2009050803 W EP2009050803 W EP 2009050803W WO 2009092810 A3 WO2009092810 A3 WO 2009092810A3
Authority
WO
WIPO (PCT)
Prior art keywords
probiotics
probiotic
pharmaceutical composition
cinetic
pharmaco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/050803
Other languages
English (en)
Other versions
WO2009092810A2 (fr
Inventor
Vygantas Kirejevas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bacterfield Oue
Original Assignee
Bacterfield Oue
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bacterfield Oue filed Critical Bacterfield Oue
Publication of WO2009092810A2 publication Critical patent/WO2009092810A2/fr
Publication of WO2009092810A3 publication Critical patent/WO2009092810A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur un procédé d'utilisation d'une combinaison d'antibiotique et de probiotique de façon contrôlée dans le temps dans une composition pharmaceutique unique, procédé suivant lequel, lors de l'utilisation de la composition pharmaceutique à une première étape du cycle pharmaco-cinétique, l'antibiotique déploie son effet contre une infection, permettant d'obtenir le taux maximal suivi par une libération contrôlée dans le temps des probiotiques. Après obtention du taux maximal, peu de temps avant la fin du cycle pharmaco-cinétique de la dose unique, la population probiotique est libérée, le temps de libération du probiotique dépendant du rapport antibiotique/probiotique, qui permet une multiplication rapide des probiotiques pour diminuer encore l'activité pathogène entre deux cycles pharmaco-cinétiques.
PCT/EP2009/050803 2008-01-24 2009-01-23 Composition pharmaceutique unique contenant des antibiotiques et des probiotiques Ceased WO2009092810A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2326308P 2008-01-24 2008-01-24
US61/023,263 2008-01-24

Publications (2)

Publication Number Publication Date
WO2009092810A2 WO2009092810A2 (fr) 2009-07-30
WO2009092810A3 true WO2009092810A3 (fr) 2009-12-17

Family

ID=40586185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/050803 Ceased WO2009092810A2 (fr) 2008-01-24 2009-01-23 Composition pharmaceutique unique contenant des antibiotiques et des probiotiques

Country Status (1)

Country Link
WO (1) WO2009092810A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036539A1 (fr) * 2009-09-23 2011-03-31 Borody Thomas J Thérapie pour infections entériques
CA2785658C (fr) * 2009-12-31 2017-10-24 Ira Milton Trachtman Compositions et procedes pour traitement et prophylaxie d'une maladie intestinale inflammatoire
ES2929893T3 (es) 2015-05-11 2022-12-02 Mybiotics Pharma Ltd Sistemas y métodos para hacer crecer una biopelícula de bacterias probióticas en partículas sólidas para la colonización de bacterias en el intestino
KR102380134B1 (ko) 2016-05-25 2022-03-29 마이바이오틱스 파마 엘티디. 미생물총 치료를 위한 조성물 및 방법
WO2020194319A1 (fr) * 2019-03-28 2020-10-01 Mybiotics Pharma Ltd. Compositions de biofilm probiotique et leurs procédés de préparation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010582A2 (fr) * 1998-08-24 2000-03-02 Ganeden Biotech, Inc. Bacteries probiotiques produisant de l'acide lactique et leurs utilisations
US6306391B1 (en) * 1997-03-27 2001-10-23 Cadila Pharmaceuticals, Ltd. Preparation of an oral pharmaceutical formulation containing an anti-infective agent and a microorganism
US20020192201A1 (en) * 1998-09-24 2002-12-19 Ira Shafran Crohn's disease treatment methods
WO2004067013A1 (fr) * 2003-01-24 2004-08-12 Flora Technology Inc. Compositions et procedes pour restaurer la flore bacterienne
EP1566176A1 (fr) * 2004-02-16 2005-08-24 Sanjeev Prem Nivas Khandelwal Formulation antibacterielle synergique et méthode de péparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306391B1 (en) * 1997-03-27 2001-10-23 Cadila Pharmaceuticals, Ltd. Preparation of an oral pharmaceutical formulation containing an anti-infective agent and a microorganism
WO2000010582A2 (fr) * 1998-08-24 2000-03-02 Ganeden Biotech, Inc. Bacteries probiotiques produisant de l'acide lactique et leurs utilisations
US20020192201A1 (en) * 1998-09-24 2002-12-19 Ira Shafran Crohn's disease treatment methods
WO2004067013A1 (fr) * 2003-01-24 2004-08-12 Flora Technology Inc. Compositions et procedes pour restaurer la flore bacterienne
EP1566176A1 (fr) * 2004-02-16 2005-08-24 Sanjeev Prem Nivas Khandelwal Formulation antibacterielle synergique et méthode de péparation

Also Published As

Publication number Publication date
WO2009092810A2 (fr) 2009-07-30

Similar Documents

Publication Publication Date Title
WO2008119012A3 (fr) Procédés et kits destinés à l'administration de probiotiques
WO2009092810A3 (fr) Composition pharmaceutique unique contenant des antibiotiques et des probiotiques
WO2009072007A3 (fr) Porteurs, formulations, procédés pour formuler des agents actifs instables pour application externe et utilisations associées
EP2136638A4 (fr) Formulations à libération modifiée de (6r)-4,5,6,7-tétrahydro-n6-propyl-2,6-benzothiazole-diamine et procédés d'utilisation de celles-ci
WO2013122931A3 (fr) Utilisation topique d'un agent prébiotique commensal dermique et compositions le contenant
IN2012DN01869A (fr)
EP2124859A4 (fr) Dispositifs, systèmes et procédés permettant de raccourcir la durée des menstruations
DK2152250T3 (da) Faste doseringsformer, der omfatter et enterisk overtræk, med accelereret lægemiddelfrigivelse
WO2015047941A3 (fr) Compositions et méthodes pour le traitement et la prophylaxie de maladies gastro-intestinales
CL2013000423A1 (es) Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno.
WO2008053232A3 (fr) Composition de réduction de la mycotoxine
WO2011120904A3 (fr) Composition pharmaceutique à dissolution rapide
BR112012004967A2 (pt) forma de dosagem oral, compreendendo pelo menos um agente biologicamente ativo, substâncias auxiliares da formulação e partículas magnetizáveis
CO6311067A2 (es) Preparación de comprimido con liberación retardada que contiene polivinilpirrolidonas y principio activo
WO2010028489A8 (fr) Microparticules à base d'amidon pour la libération d'agents disposés dans celles-ci
WO2010141606A3 (fr) Cellules souches gonadales humaines
WO2011077239A3 (fr) Compositions pharmaceutiques d'ilopéridone à libération lente
WO2012047663A3 (fr) Procédés comprenant des composés à fonction 1,3-dipôle latents et matériaux préparés par ces procédés
IL213255A0 (en) Process for the preparation of random radical copolymers, and active substance compositions obtainable therefrom
WO2011048554A3 (fr) Association d'un lysat de probiotique et d'un derive c-glycoside
PA8802901A1 (es) Recubrimiento mejorado de tableta
EP1988725A4 (fr) Procédé et dispositif pour libérer un droit de parole
GB201105050D0 (en) Pharmaceutical agent
WO2011047277A3 (fr) Libération d'agents par des cellules
WO2012177075A3 (fr) Composition contenant des antibiotiques et de la lysophosphatidylcholine, dans le renforcement de l'immunité ou le traitement d'infections bactériennes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09704844

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09704844

Country of ref document: EP

Kind code of ref document: A2